Cholesterol, ApoB and the lipoprotein profile
"High cholesterol" is one of the most over- and under-interpreted lab results in modern medicine. What clinically matters is not total cholesterol or even LDL-C alone, but the particle count (ApoB), their size (phenotype A vs B), Lp(a) and inflammatory markers such as hs-CRP, homocysteine and fibrinogen.
- ApoB > LDL-C — measures the actual particle count
- Small dense LDL (phenotype B) is many times more dangerous
- Lp(a), hs-CRP, homocysteine, fibrinogen — often forgotten, clinically decisive
What is cholesterol and why the standard panel misses half the picture
Cholesterol is not a "bad substance". It is the raw material for every cell membrane, for hormones (testosterone, oestrogen, cortisol) and for vitamin D. The liver produces ~80% of circulating cholesterol; only ~20% comes from food.
Water-insoluble cholesterol is transported in the blood inside lipoproteins — LDL, VLDL, IDL, HDL and Lp(a). Every such particle carries apolipoprotein B (ApoB) on its surface, except HDL which carries ApoA. Measuring ApoB gives a direct count of potentially atherogenic particles — something traditional "LDL cholesterol" (in grams) cannot do.
Two people with the same LDL-C (say 3.5 mmol/L) can have very different risk: one carries large, fluffy, low-count LDL particles (phenotype A — low risk), the other many small, dense LDL particles (phenotype B — high risk). Same mass, very different particle behavior.
Clinical signs and red-flag profile
- Trig/HDL ratio >1.5 — indirect sign of phenotype B and insulin resistance
- Family history of early heart attack (men <55, women <65)
- Diagnosed familial hypercholesterolaemia (FH)
- Xanthelasma (yellow eyelid plaques), arcus corneae before age 50
- Vascular thickening on carotid or abdominal ultrasound
- Metabolic syndrome: abdominal fat + high BP + insulin resistance
- Chronic inflammatory state (autoimmune, periodontitis, IBD)
- Smoking and chronic stress — accelerate atherosclerosis even at "normal" LDL
Why ApoB is better than LDL-C
An atherosclerotic plaque forms when an ApoB-carrying particle crosses the endothelium and gets stuck. What counts is how many particles are at the door — not how many grams of cholesterol they carry. Every LDL/VLDL/IDL/Lp(a) particle carries one ApoB molecule — so ApoB = direct particle count.
Large studies (Sniderman, Circulation 2019; INTERHEART) show ApoB predicts cardiovascular events more accurately than LDL-C. This especially matters in discordance: someone with "normal" LDL-C but high ApoB is still at high risk.
Particle size: phenotype A vs B
- Phenotype A — large, fluffy LDL, fewer particles, lower risk
- Phenotype B — small, dense LDL (sdLDL), more particles, higher risk
- Phenotype B arises with insulin resistance, high triglycerides and low HDL
- Trig/HDL >1.5 (mmol/L) or >3.5 (mg/dL) = strong indirect sign of phenotype B
- sdLDL more easily enters the endothelium and is more oxidation-prone — hence more atherogenic
Four pillars to improve the lipid profile
A statin is one tool. Before, alongside and after sits lifestyle, which directly changes particle number, size and inflammatory context.
Nutrition
Cut refined carbs and liquid sugar — the main drivers of triglycerides and phenotype B. Fiber (30 g+/day), omega-3, monounsaturated fats (olive oil, avocado, nuts). Losing 5–10% of body weight often drops ApoB by 15–25%.
Insulin sensitivity
Phenotype B and high triglycerides are 90% downstream of insulin resistance. Lower insulin — eating window 8–10 h, strength training, sleep — and the lipid profile improves more than with drugs alone.
Supplements to support lipids and vascular health
Supplements don't replace statins when clinically indicated — that decision belongs with your doctor. But several complement lifestyle effectively and move markers statins don't touch.
- Omega-3 (EPA/DHA, 2–4 g/day) — lowers triglycerides 20–30%, reduces inflammation
- Berberine — lowers LDL-C and ApoB ~15%, improves insulin sensitivity; watch drug interactions
- Red-yeast rice (monacolin K) — statin-like action; don't combine with a statin
- B12, folate (methyl forms), B6, betaine (TMG) — lower homocysteine
- Vitamin K2 (MK-7) — routes calcium into bone, not arteries (paired with D)
- CoQ10 (ubiquinol) — mitochondrial support, especially on a statin
- Nattokinase — lowers fibrinogen with fibrinolytic action (data emerging)
- Plant sterols / fiber (psyllium) — reduce cholesterol absorption in the gut
Fasting and the lipid profile
Time-restricted eating and periodic fasting lower triglycerides, shift LDL towards phenotype A and reduce ApoB — indirectly via improved insulin sensitivity.
Tinsley et al. (2019, Am J Clin Nutr): 16:8 combined with resistance training improved the lipid profile and body composition in adults with excess weight, including triglycerides and fat mass.
Not appropriate in pregnancy, lactation, eating-disorder history or on certain medications (insulin, sulfonylureas) without supervision.
Expanded lipid panel — what to ask for
- ApoB — direct atherogenic-particle count (target <0.9 g/L, high risk <0.65)
- Lp(a) — at least once in life (target <30 mg/dL / <75 nmol/L)
- LDL-C, HDL-C, triglycerides, total cholesterol (standard panel)
- Trig / HDL ratio — indirect phenotype B and IR marker
- Non-HDL cholesterol — all atherogenic particles combined
- hs-CRP — vascular inflammation (target <1 mg/L)
- Homocysteine (target <8 μmol/L)
- Fibrinogen (target <3.5 g/L)
- Fasting insulin and HOMA-IR — root cause of phenotype B
- Thyroid (TSH, free T3) — hypothyroidism raises LDL
- Vitamin D, ferritin — systemic context
- Coronary artery calcium score (CAC) from age 40 — direct plaque burden
Go deeper: lipidology and cardiovascular webinars
Recorded webinars on ApoB, lipoproteins and cardiovascular risk assessment — with Dr Saadi.
Lipiidiprofiili sihttasemed
Sihtväärtused sõltuvad kardiovaskulaarsest riskist (ESC 2019, EAS 2022)
| Marker | Madal risk | Mõõdukas / kõrge risk | Väga kõrge risk |
|---|---|---|---|
| LDL-kolesterool | < 3,0 mmol/l | < 2,6 mmol/l | < 1,4 mmol/l |
| ApoB | < 100 mg/dl | < 80 mg/dl | < 65 mg/dl |
| Triglütseriidid | < 1,7 mmol/l | < 1,5 mmol/l | < 1,5 mmol/l |
| HDL-kolesterool (M / N) | > 1,0 / > 1,2 mmol/l | sama | sama |
| Lp(a) | < 30 mg/dl (< 75 nmol/l) | sama | sama |
| Non-HDL kolesterool | < 3,8 mmol/l | < 3,4 mmol/l | < 2,2 mmol/l |
| Homotsüsteiin | < 10 µmol/l | < 10 µmol/l | < 10 µmol/l |
LDL-kolesterool
- Madal risk
- < 3,0 mmol/l
- Mõõdukas / kõrge risk
- < 2,6 mmol/l
- Väga kõrge risk
- < 1,4 mmol/l
ApoB
- Madal risk
- < 100 mg/dl
- Mõõdukas / kõrge risk
- < 80 mg/dl
- Väga kõrge risk
- < 65 mg/dl
Triglütseriidid
- Madal risk
- < 1,7 mmol/l
- Mõõdukas / kõrge risk
- < 1,5 mmol/l
- Väga kõrge risk
- < 1,5 mmol/l
HDL-kolesterool (M / N)
- Madal risk
- > 1,0 / > 1,2 mmol/l
- Mõõdukas / kõrge risk
- sama
- Väga kõrge risk
- sama
Lp(a)
- Madal risk
- < 30 mg/dl (< 75 nmol/l)
- Mõõdukas / kõrge risk
- sama
- Väga kõrge risk
- sama
Non-HDL kolesterool
- Madal risk
- < 3,8 mmol/l
- Mõõdukas / kõrge risk
- < 3,4 mmol/l
- Väga kõrge risk
- < 2,2 mmol/l
Homotsüsteiin
- Madal risk
- < 10 µmol/l
- Mõõdukas / kõrge risk
- < 10 µmol/l
- Väga kõrge risk
- < 10 µmol/l
Väga kõrge risk = varasem infarkt/insult, diabeet + kahjustus, krooniline neerukahjustus, familiaalne hüperkolesteroleemia. ApoB on täpsem kui LDL üksi.
Frequently asked questions
Go deeper: related materials
Related topics
Metabolic health is interconnected — explore the other deep-dives:
Insulin resistance
The root of metabolic disease — 5–10 years before diabetes appears.
ReadOverweight
Why calorie counting fails — hormones, insulin, leptin and adipose tissue.
ReadVagus nerve
The rest-and-repair system — digestion, heart, inflammation, stress.
ReadSleep
The foundation of metabolic health — hormones, cortisol, insulin, brain recovery.
ReadChronic inflammation
The 'silent fire' behind cardiovascular disease, diabetes and autoimmunity.
ReadLow-carb and keto
Carbohydrate restriction — IR, T2D, fatty liver, metabolic syndrome.
ReadTeaduslikud allikad
- Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2020. doi.org/10.1093/eurheartj/ehz455
- Sniderman AD et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 2019. doi.org/10.1001/jamacardio.2019.3780
- Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis (EAS Consensus Statement). European Heart Journal, 2022. doi.org/10.1093/eurheartj/ehac361
- Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). NEJM, 2019. doi.org/10.1056/NEJMoa1812792
- Jenkins DJA et al. Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs. Statin. JAMA, 2003. doi.org/10.1001/jama.290.4.502
- Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies (EAS Consensus). European Heart Journal, 2017. doi.org/10.1093/eurheartj/ehx144
- Sacks FM et al. Dietary Fats and Cardiovascular Disease (AHA Presidential Advisory). Circulation, 2017. doi.org/10.1161/CIR.0000000000000510
- Cannon CP et al. Ezetimibe added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). NEJM, 2015. doi.org/10.1056/NEJMoa1410489
Dr Sergey Saadi — expert in advanced lipidology and metabolic health
Dr Sergey Saadi is a physician with over 15 years of clinical practice.
- Clinical approach: ApoB + Lp(a) + hs-CRP + homocysteine + fibrinogen — not just LDL-C
- Regular speaker in media and in clinician training
- Author of "Dangerous secrets of blood sugar" (Varrak)
Want to know your real cardiac risk?
In the consultation we review your expanded lipid panel (ApoB, Lp(a), hs-CRP, homocysteine, fibrinogen), the CAC score and build an individual plan you can discuss with your GP and/or cardiologist.
Book a consultationThis page is educational and general. It is not personal medical advice, a diagnosis or a treatment plan. Discuss changes with your doctor.